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Abstract. Terpinen-4-ol (TP4O) is the main component of the 
essential oil extracted from Melaleuca alternifolia, known as 
the tea tree, of the botanical family Myrtaceae. The anticancer 
effects of TP4O have been reported in several cancer cell 
lines. Previous reports have demonstrated that TP4O exerts 
anticancer effects by inducing apoptotic cell death in several 
cell lines; however, the underlying molecular mechanisms of 
these effects remain unclear. In the present study, the anti-
cancer effects of TP4O against the colorectal cancer (CRC) 
cell lines HCT116 and RKO were evaluated using WST-8 and 
bromodeoxyuridine assays. The mechanism of cell death was 
investigated by the measurement of caspase-3/7, Annexin V 
and lactate dehydrogenase release. Reactive oxygen species 
(ROS) levels induced by TP4O were evaluated by electron spin 
resonance and quantitative measurement of dihydroethidium. 
Localization of the ROS derived from mitochondria was 
observed by confocal inverted microscopy. Protein levels of 
ROS scavengers were assessed by western blotting analysis. 
To confirm the role of ROS, cell viability was measured in 
the presence of antioxidant reagents. In an in vivo xenograft 
model of ICR-SCID mice implanted with HCT116 cells, 
200 mg/kg TP4O was injected locally, and tumor growth was 
compared with that of the control. TP4O induced apoptotic 
cell death in HCT116 and RKO cells in a dose-dependent 
manner, and TP4O also increased the levels of ROS generated 
by mitochondria. TP4O-induced cell death was rescued by 
administration of antioxidant regents. In vivo, TP4O inhibited 
the proliferation of HCT116 xenografts compared with that of 
the control group. The results of the present study suggest that 
TP4O induces apoptosis in CRC cells through ROS generation. 
Furthermore, TP4O is potentially useful for the development 
of novel therapies against CRC.
Introduction
Colorectal cancer (CRC) is the third most common cancer in 
males and the second in females worldwide (1). For patients 
in the early stages of CRC, i.e., stages I and II, surgery is 
the most common treatment, and the 5-year relative survival 
for patients with early-stage CRC is 90.3%. By contrast, for 
patients with advanced CRC, chemotherapy and/or radiation 
therapy is required, and the 5-year survival rate of patients 
with distant metastasis is 12.5% (2). The ideal anticancer drug 
would be one that is affordable, has few side effects and is 
sufficiently potent to achieve complete remission. Inhibitors of 
vascular endothelial growth factor and monoclonal antibodies 
that inhibit epidermal growth factor receptor have prolonged 
the survival of advanced CRC patients (3,4). However, these 
drugs have severe side effects, and thus, researchers have 
been searching for novel biochemical compounds (5). Natural 
products have become an important resource for novel drug 
discovery (5), and >50% of anticancer drugs are derived from 
natural products (6).
Essential oils are natural products extracted from seeds, 
leaves and tree resin. These natural oils are used primarily 
in perfumes, cosmetics and the food industry (7). Various 
of these oils have been demonstrated to possess antibiotic, 
anti‑inflammatory and anticancer properties (7,8). The molec-
ular mechanisms underlying their anticancer effects have been 
revealed to occur via reactive oxygen species (ROS) signaling 
pathways and cell cycle arrest (9,10). Terpinen-4-ol (TP4O) 
is the main component of the essential oil extracted from 
Melaleuca alternifolia (of the botanical family Myrtaceae), a 
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plant native to Australia that is also known as the tea tree (11). 
Tea tree oil (TTO) is famous for its scent, and has been demon-
strated to have antibacterial (11,12) and anti‑inflammatory 
properties (13). Previous studies have investigated the anti-
cancer effect of TP4O against human melanoma cells (14), 
human non-small cell lung cancer (15), human leukaemia 
cells (16) and CRC cells (17). However, the anticancer effects 
of TPO4 remain unclear. In the present study, the anticancer 
effects of TP40 against CRC cells, in particular the role of 
ROS, were evaluated using the HCT116 and RKO cell lines.
Materials and methods
Chemicals and reagents. TP4O, Triton X-100, staurosporine 
and ebselen (EB) were purchased from Sigma-Aldrich (Merck 
KGaA, Darmstadt, Germany). TP4O was dissolved in ethanol 
to prepare stock solutions. The compound was administered 
at a final concentration of 0.0165% ethanol. High-glucose 
(4.5 g/l) Dulbecco's modified Eagle's medium (DMEM), 
phenol red-free DMEM and PBS were purchased from 
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Eagle's 
minimum essential medium (EMEM) was purchased from 
the American Type Culture Collection (ATCC; Manassas, 
VA, USA). 5,5-dimethyl-l-pyrroline-N-oxide (DMPO) 
was purchased from Dojindo Molecular Technologies, 
Inc. (Kumamoto, Japan). N-acetyl-L-cysteine (NAC) and 
manganese (III) tetrakis (4-benzoic acid) porphyrin chloride 
(MnTBAP) were purchased from EMD Millipore (Billerica, 
MA USA) and Funakoshi Co., Ltd. (Tokyo, Japan), respec-
tively. Phenylmethylsulfonyl fluoride was purchased from 
Roche Diagnostics GmbH (Mannheim, Germany).
Cell lines and cell culture. Human CRC cell lines (HCT116 
and RKO) and a human normal colon epithelial cell line (CCD 
841 CoN) were purchased from the ATCC. The cancer cell 
lines were cultured in DMEM, while CCD 841 CoN cells 
were cultured in EMEM. The media were supplemented 
with 10% heat-inactivated foetal bovine serum (FBS) and 1% 
antibiotics (100 U/ml penicillin). All cell lines were incubated 
at 37˚C and maintained in an incubator with 5% CO2. All 
cells were used while within a passage number that ranged 
between 8 and 21. Cells were seeded at 5,000 cells/well in 
96-well plates for the WST-8 and bromodeoxyuridine (BrdU) 
assays, at 10,000 cells/well in 96-well plates for the lactate 
dehydrogenase (LDH) release assay, at 2x105 cells/well in 
6-well plates for the caspase-3/7 and Annexin V assays, and at 
1x106 cells/dish in 6-cm dishes for western blot analysis. Each 
cell line was seeded in the above culture media and incubated 
for 24 h prior to each experiment.
Evaluation of cell viability and proliferation. To evaluate the 
effects of TP4O on cell viability and proliferation, WST-8 and 
BrdU assays were performed. Briefly, cells were pre‑incubated 
for 24 h and treated with various concentrations of TP4O for 
24 h (0, 1, 10, 100, 1,000 or 10,000 µM). Cell viability was 
quantified using a WST‑8 assay via the Cell Counting kit‑8 
(Dojindo Molecular Technologies, Inc.) by measuring the 
absorbance at 450 nm. Cell proliferation was quantified using 
a BrdU assay kit purchased from Roche Diagnostics GmbH 
by measuring the absorbance at 370 nm. The half maximal 
inhibitory concentration (IC50) values for each cell line were 
determined over 24 h following TP4O treatment. Cell viability 
following treatment with antioxidants was also measured. 
Following pre‑incubation of the cells for 24 h at 37˚C, the 
culture medium was exchanged for medium with antioxidants 
(20 mM NAC, 20 µM EB and 100 µM MnTBAP) 30 min prior 
to TP4O administration. The results were obtained from three 
independent experiments.
Evaluation of apoptosis. To evaluate apoptosis, the 
following flow cytometry experiment was performed. After 
24 h of pre‑incubation at 37˚C, the cells were treated with 
various concentrations of TP4O (0, 100 or 1,000 µM). 
Treatment-induced caspase-3/7 activation was examined in 
HCT116 and RKO cells using the Muse™ Cell Analyzer 
(Merck KGaA) and Muse™ Caspase-3/7 Assay kit (Merck 
KGaA), according to the manufacturer's protocol. Following 
6 h of treatment, harvested cells were mixed with the Muse™ 
Caspase-3/7 reagent, which contains a DNA-binding dye that 
is linked to a DEVD peptide substrate and a dead cell marker 
[7-aminoactinomycin D (7-AAD)]. Caspase-3/7 activity was 
detected with the fluorescence of a DNA‑binding dye from 
the Muse™ Caspase-3/7 Assay kit and cell viability was 
detected with 7‑AAD fluorescence using the Muse™ Cell 
Analyzer. The results were obtained from three independent 
experiments.
For the Annexin V assay, cells were treated with TP4O 
(0, 100 or 1,000 µM) for 12 h. Treatment-induced apoptosis 
was examined using the Muse™ Annexin V & Dead Cell 
kit (Merck KGaA) according to the manufacturer's protocol. 
Phosphatidylserine (PS) was detected using Annexin V, 
and cell viability was detected using a dead cell marker 
(7-AAD). The results were obtained from four independent 
experiments.
LDH‑release assay. An LDH-release assay was performed 
to assess necrosis resulting from TP4O treatment. The LDH 
Cytotoxicity Detection kit (Takara Bio, Inc., Otsu, Japan) 
quantifies the activity of LDH released from damaged 
cells (18). Following 24 h of pre-incubation, the culture 
medium was exchanged for FBS-free DMEM containing 1% 
Triton X-100, various concentrations of TP4O (0, 10, 100 or 
1,000 µM) and 200 nM staurosporine for 12 h. Following 
treatment, the plates were centrifuged at 250 x g for 10 min 
at 4˚C. The supernatant was transferred to a clear 96‑well 
plate, and 100 µl of reaction mixture was then added to each 
well. The plates were incubated in the dark for 30 min at 25˚C, 
the absorbance was measured at 490 nm and the percentage 
LDH release was calculated. To compare necrotic cell death, 
samples with 1% Triton X-100 were used as positive controls. 
To study apoptotic cell death, LDH release induced by 200 nM 
staurosporine was examined. The results were obtained from 
three independent experiments.
Electron spin resonance (ESR) measurement. ROS 
generation in cells was measured using ESR, as previously 
described (19). Briefly, 106 cells were seeded on a glass cover 
slide (49.0x5.0x0.2 mm) and incubated overnight as previously 
described. Cells were treated with 0 or 1,000 µM TP4O for 
15 min. ESR was measured in a respiration buffer containing 
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10 mM DMPO as the spin-trapping agent. All ESR spectra 
were obtained using a JES-RE1X X-band spectrometer (JEOL, 
Ltd., Tokyo, Japan).
Detection of mitochondrial superoxide. The source of 
superoxide was detected by fluorescence microscopy. A total 
of 2.5x104 cells/well were seeded in an 8-well cover glass 
chamber. After 24 h of pre-incubation, cells were treated with 
0 or 1,000 µM TP4O for 24 h. Culture medium was exchanged 
for phenol red-free DMEM, which contained 5 µM MitoSOX 
Red™ Mitochondrial Superoxide Indicator (Molecular 
Probes; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 
and the cells were incubated for 10 min at 37˚C. Following one 
wash with PBS, the cells were incubated for a further 30 min 
at 37˚C with phenol‑free DMEM, which contained 100 nM 
MitoTracker Green FM™ (Molecular Probes; Thermo Fisher 
Scientific, Inc.). Next, the cells were washed with PBS and 
observed using a confocal inverted fluorescence microscope 
(Olympus Corporation, Tokyo, Japan). Localization of ROS 
derived from mitochondria was detected by MitoSOX Red™ 
Mitochondrial Superoxide Indicator fluorescence, and local-
ization of mitochondria was detected by MitoTracker Green 
FM™ fluorescence. Images of bifocal field, MitoSOX Red™ 
Mitochondrial Superoxide Indicator and MitoTracker Green 
FM™ were merged.
Quantification of oxidative stress. The quantitative measure-
ment of cellular populations undergoing oxidative stress 
was measured using the Muse™ Cell Analyzer and Muse™ 
Oxidative Stress kit (Merck KGaA). Cells were seeded at 
2x105 cells/well in a 6-well plate and incubated overnight. 
Following exposure to 0 or 1,000 µM TP4O for 24 h, 
according to the manufacturer's protocol, cells were detached, 
resuspended at 1x106 cells/ml and incubated at 37˚C for 
30 min with Muse™ Oxidative Stress working solution, which 
contained dihydroethidium (DHE). DHE is cell permeable, 
and has been proposed to react with superoxide anions, thus 
undergoing oxidation upon binding to DNA (20). The number 
of oxidized cells were counted according to the intensity of red 
fluorescence using the Muse™ Cell Analyzer. The results were 
obtained from four independent experiments.
Western blot analysis. Cells were seeded at 1x106 cells/dish 
in 6-cm dishes. After 24 h, cells were treated with various 
concentrations of TP4O (0, 100 or 1,000 µM) for 24 h. 
Cultured cells were washed with PBS and lysed with lysis 
buffer that contained 1% Protease Inhibitor Cocktail (100X; 
Cell Signaling Technology, Inc., Danvers, MA, USA) and 
1 mM phenylmethylsulfonyl fluoride. Samples were kept on 
ice for 2 min, followed by sonication for 5 min and centrifuga-
tion at 13,000 x g for 2 min at 4˚C; the supernatants were then 
collected. The samples were subjected to 15% SDS-PAGE and 
transferred to a polyvinylidene fluoride membrane (Merck 
KGaA). After 30 min blocking with Tris-buffered saline 
containing 0.1% Tween-20 (T-TBS) and 5% bovine serum 
albumin (Iwai Chemicals Company, Ltd., Tokyo, Japan), 
primary antibodies against superoxide dismutase 2 (SOD2; 
cat. no. 13141; dilution, 1:1,000) glutathione peroxidase 1 
(GPX1; cat. no. 3206; dilution 1:500) and GAPDH (endogenous 
control; cat. no. 2118; dilution, 1:1,000; all from Cell Signalling 
Technology, Inc.) were incubated with membranes in Can Get 
Signal® Immunoreaction Enhancer Solution 1 (Toyobo Co., 
Ltd., Osaka, Japan) overnight at 25˚C. After washing 3 times 
for 30 min with T-TBS, the membrane was incubated with an 
anti-rabbit IgG, horseradish perxodiase-linked antibody (cat. 
no. 7074; dilution, 1:1,000; Cell Signalling Technology, Inc.) 
in Can Get Signal® Immunoreaction Enhancer Solution 2 
(Toyobo Co., Ltd.) for 2 h at 25˚C. After washing 3 times for 
15 min with T‑TBS at 25˚C, the bands were incubated with 
ECL™ Western Blotting Detection reagents as according to 
the manufacturer's protocol and detected with ImageQuant 
LAS 4000 mini (both from GE Healthcare Life Sciences, 
Chalfont, UK). Results were quantified using ImageQuant TL 
7.0 software (GE Healthcare Life Sciences).
Animals. A total of 14 male ICR-SCID mice aged 6-7 weeks 
old and weighing 21-25 g were purchased from Charles River 
Laboratories Japan, Inc. (Yokohama, Japan). The mice were 
provided with clean water and food ad libitum, and housed in 
standardized, pathogen-free conditions with a 14 h light/10 h 
dark cycle, a temperature of 23.5±2.5˚C and humidity of 
52.5±12.5%. The mice were used after an acclimation period 
of ≥7 days. All animal experiments were performed with the 
approval of the Animal Ethics Committee of the University of 
Tsukuba (Tsukuba, Japan; approval no. 13-385) and according 
to the guidelines of this committee.
Xenograft model. To evaluate the effect of TP4O in vivo, a 
subcutaneous tumor was induced. HCT116 cells (2x106 cells 
per mouse) were injected subcutaneously into the right flanks 
of 14 mice. Tumor volume was calculated using the following 
formula: 0.5 x length x width2. When tumor volume had 
reached 80-100 mm3, the 12 qualifying mice were randomly 
divided into two groups (n=6/group) and subcutaneously 
injected with one of the following: 250 µl saline (control group) 
or 200 mg/kg TP4O dissolved in 250 µl saline (TP4O group). 
Each mouse was injected once every 3 days (total, five times). 
The tumor volume was recorded every 3 days. Body weight 
was recorded the first day of the injection, on day 7 and at 
the end of experimentation (day 14). On day 14, blood samples 
were collected under anesthesia, the mice were sacrificed and 
the tumors were excized. To evaluate TP4O toxicity, serum 
alanine aminotransferase (ALT) and serum creatinine levels 
were measured using an autoanalyzer (Dri-chem 7000 V; 
Fujifilm, Tokyo, Japan).
Immunostaining. The tumor tissue was fixed with 10% 
formaldehyde. Each 2-µm paraffin-embedded section was 
stained with an anti-8-hydroxy-2'-deoxyguanosine (8-OHdG) 
antibody at 4˚C overnight (cat. no. MOG‑20P; dilution, 1:100, 
Japan Institute for the Control of Aging, Shizuoka, Japan) 
or with an anti-cleaved caspase-3 antibody according to the 
manufacturer's protocol (cat. no. 9661; dilution, 1:300; Cell 
Signaling Technology, Inc.). 8-OHdG is a marker for oxida-
tive stress (21). To accurately quantify 8-OHdG- and cleaved 
caspase-3-positive areas, slides from three randomly selected 
high‑power fields (magnification, x200) of each tumor were 
visualized using a BZ-X710 microscope (Keyence Corporation, 
Osaka, Japan). An automated software analysis program, 
BZ-X analyser version 1.3.0.3 (Keyence Corporation), was 
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used to determine the percentage of stained areas in the digital 
photomicrographs.
Statistical analysis. The data are expressed as the mean ± stan-
dard deviation. For comparison of >2 groups, analysis of 
variance (ANOVA) was performed. If the ANOVA results were 
significant, a Dunnett's test for comparison with the control 
was used. For comparison of two groups, an unpaired Student's 
t-test was performed. All indicated P-values were two-sided, 
and P<0.05 was considered to indicate a statistically signifi-
cant difference. All statistical analyses were performed using 
GraphPad Prism software version 5.01 (GraphPad Software, 
Inc., La Jolla, CA, USA).
Results
TP4O inhibits CRC cell viability and proliferation. To eval-
uate cytotoxicity following TP4O treatment, cell viability was 
measured using a WST‑8 assay. TP4O significantly decreased 
the viability of the human CRC cell lines HCT116 at 100, 1,000 
and 10,000 µM, and RKO at 1,000 and 10,000 µM (Fig. 1A). 
The effect of TP4O was dose dependent. The IC50 values 
of TP4O in HCT116 and RKO cells were 661 and 381 µM, 
respectively. By contrast, the IC50 value of TP4O in the normal 
human colon epithelial cell line CCD 841 CoN was 5,347 µM. 
In addition, TP4O significantly inhibited cell proliferation 
in a dose-dependent manner in CRC cell lines and CCD 841 
CoN cell line, particularly in the CRC cell lines at 1,000 µM 
(Fig. 1B).
TP4O induces apoptotic cell death in CRC cells. 
TP4O-induced apoptotic cell death was determined using a 
caspase-3/7 activity assay and Annexin V assay. DNA frag-
mentation and exposure of PS are typical phenomena observed 
in apoptotic cell death (22). Caspase-3/7 activity was enhanced 
in TP4O-treated cells in a dose-dependent manner (Fig. 2A). 
The distribution of apoptotic cells, which were located in the 
top- and bottom-right quadrants, is presented in a bar graph; 
the percentage of apoptotic cells was significantly increased in 
cells treated with 1,000 µM TP4O compared with 0 µM TP4O 
(P<0.05; Fig. 2B). Although there was no statistical difference, 
the percentage of Annexin V-positive cells tended to increase 
in HCT116 and RKO cell cultures treated with 1,000 µM TP4O 
(Fig. 2C and D). The lower level of LDH release following 
TP4O treatment indicates that TP4O did not induce necrotic 
LDH release in HCT116, RKO (Fig. 2E) or CCD 841 CoN 
(data not shown) cell lines.
TP4O generates ROS in CRC cells, and TP4O‑induced cell 
death is rescued by antioxidant reagents. In the presence of 
Figure 1. TP4O causes cell death and inhibits cell proliferation in human CRC cell lines. (A) Cell viability was measured using the WST-8 assay. HCT116, RKO 
and CCD 841 CoN cells were treated with the indicated concentrations of TP4O for 24 h. Values were compared with 0 µM TP4O as the control, which was 
considered 100%. Cell viability was decreased in CRC cells in a dose-dependent manner. The IC50 values of TP4O in HCT116 and RKO cells were 661 and 
381 µM, respectively. The IC50 value of TP4O in the human normal colon epithelial cell line CCD 841 CoN was 5,347 µM. (B) Cell proliferation was measured 
using a bromodeoxyuridine assay. HCT116, RKO and CCD 841 CoN cells were treated with the indicated concentrations of TP4O for 24 h. The values were 
compared with those obtained with 0 µM TP4O, which served as the control (100%). The percentage of cell proliferation decreased in a dose-dependent 
manner. The data are represented as the mean ± standard deviation. *P<0.05. **P<0.01. The results were obtained from three independent experiments. TP4O, 
terpinen-4-ol; CRC, colorectal cancer; IC50, half maximal inhibitory concentration.
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DMPO, the hydroxyl radical can be detected as as four spikes 
in ESR (23). ESR measurements revealed that treatment with 
1,000 µM TP4O for 15 min induced the generation of the 
hydroxyl radical in CRC cells (Fig. 3A), whereas the hydroxyl 
radical was barely detectable in CCD841 CoN cells (data not 
shown). The increase in oxidative stress was quantified by DHE 
reaction. TP4O administration led to an increase in the number 
of cells with high ROS (Fig. 3B). There was a significant increase 
in oxidative stress in HCT116 cells (P<0.05; Fig. 3C). This result 
implies that TP4O enhances the accumulation of intracellular 
ROS in HCT116 cells. There was a non‑significant increase 
observed in RKO cells following the administration of TP4O.
Figure 2. TP4O induces the apoptosis of human CRC cell lines. (A) HCT116 and RKO cells were treated with the indicated concentrations of TP4O for 6 h. 
Caspase‑3/7 activity and cell viability were measured by flow cytometry. Caspase‑3/7 activity was detected by fluorescence of a DNA‑binding dye and cell 
viability were detected with the detection of 7‑aminoactinomycin D fluorescence using the Muse™ Cell Analyzer. (B) The percentage of apoptotic cells, which 
are located in the top- and bottom-right quadrants, is presented. The values were compared with those obtained with 0 µM TP4O. The data are presented as the 
mean ± SD. *P<0.05. The results were obtained from three independent experiments. (C) HCT116 and RKO cells were treated with the indicated concentrations 
of TP4O for 12 h. The extent of apoptosis was measured with Annexin V staining. (D) The percentage of apoptotic cells, which are located in the top- and 
bottom-right quadrants, is presented. The values were compared to with those obtained with 0 µM TP4O. The data are presented as the mean ± SD. The 
results were obtained from four independent experiments. (E) HCT116 and RKO cells were treated with the indicated concentrations of TP4O for 12 h, and 
the LDH level in the supernatant was measured. The values were compared with those obtained with 1% Triton X-100 as the control (100%). To determine 
whether LDH release was associated with necrosis or apoptosis, cells were treated with Triton X-100 or staurosporine, respectively. The data are represented 
as the mean ± SD. **P<0.01. The results were obtained from three independent experiments. TP4O, terpinen-4-ol; CRC, colorectal cancer; IC50, half maximal 
inhibitory concentration; SD, standard deviation; LDH, lactate dehydrogenase; Apop., apoptosis.
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To determine the source of TP4O-induced ROS, CRC 
cells were observed by confocal inverted fluorescence micros-
copy. The location of the mitochondria was represented by 
MitoTracker Green FM™ fluorescence, while accumulated 
ROS were represented by MitoSOX Red™ Mitochondrial 
Superoxide Indicator f luorescence. The merged image 
Figure 3. TP4O induces ROS in human CRC cell lines. (A) ESR measurement. HCT116 and RKO cells were treated with 0 or 1,000 µM of TP4O for 15 min. 
ESR was measured in a respiration buffer containing 5,5-dimethyl-1-pyrroline-N-oxide as the spin-trapping agent. The production of the hydroxyl radical 
was detected with four spikes in ESR. Spikes derived from the hydroxyl radical (indicated with arrows) became apparent in cells exposed to 1,000 µM TP4O. 
(B) Quantitative measurements of cellular populations undergoing oxidative stress, based on the detection of ROS. HCT116 and RKO cells were untreated or 
treated with 1,000 µM TP4O for 24 h. The distribution of cells according to levels of intracellular ROS was represented as a histogram. Cells were divided 
into two groups: The blue area (M1) represented the cells with low ROS, and the red area (M2) represented the cells with high ROS. The administration of 
TP4O led to an increase in the number of cells in the red area. (C) The mean fluorescence intensity of each group is presented. The values were compared 
with those obtained with 0 µM TP4O. The data are presented as the mean ± SD. *P<0.05. The results were obtained from four independent experiments. 
TP4O, terpinen-4-ol; CRC, colorectal cancer; IC50, half maximal inhibitory concentration; SD, standard deviation; ROS, reactive oxygen species; DHE, 
dihydroethidium; ESR, electron spin resonance.
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demonstrated that the ROS induced by TP4O were generated 
by mitochondria (Fig. 4).
Protein levels of intrinsic oxidant scavengers were analysed 
by western blotting. Protein levels of SOD2 and GPX1 tended 
to increase following exposure to TP4O (Fig. 5A). However, 
there was no significant difference in comparison with that of 
0 µM TP4O (Fig. 5B). The results suggested that ROS accumu-
lation was not due to suppression of ROS scavengers, but due to 
increased ROS production. CRC cells were exposed to specific 
antioxidants (NAC, EB and MnTBAP), which prevented 
significant TP4O‑derived cell death (Fig. 5C), demonstrating 
that ROS accumulation was the cause for cell death.
TP4O treatment inhibits tumor growth in a xenograft mouse 
model. A schematic representation of the experimental design 
is provided in Fig. 6A. Mice treated with TP4O developed 
significantly smaller tumors compared with the group treated 
with vehicle (P<0.05; Fig. 6B). TP4O administration did not 
cause marked complications or body weight loss, and the 
serum levels of ALT and creatinine were not different in 
the TP4O group compared with those in the control group 
(Fig. 6C). For the histological analysis, tumors were stained 
using antibodies against the oxidative stress marker 8-OHdG. 
The areas of anti-8-OH-dG staining were larger in tissues from 
the TP4O group compared with those from the control group 
(Fig. 6D). In addition, areas stained by anti-cleaved caspase-3 
antibody were larger in the TP4O group than in the control 
group (Fig. 6D).
Discussion
TP4O is an essential oil extracted from aromatic plants and is 
a type of monoterpene (10). Monoterpenes, the C10 class of 
isoprenoids, are a diverse family of natural products, ranging 
in structure from linear to polycyclic (24). Menthol, limonene, 
eucalyptol and citral are familiar monoterpenes that are used 
as food and cosmetic additives (8,24).
The anticancer effects of essential oils have previ-
ously been investigated by biological approaches focusing 
on pharmaceutical and therapeutic potentials of essential 
oils (7,9,10,25). Previous studies have indicated that the anti-
cancer effects of TPO4 are due to the induction of apoptosis 
in human melanoma cells (14), human non-small cell lung 
cancer (15), human leukaemia cells (16) and CRC cells (17). 
However, Greay et al (26) reported that TP4O induces necrosis 
and cell cycle arrest in murine mesothelioma and melanoma 
cells. In the present study, TP4O elevated caspase-3/7 activity 
and increased the number of Annexin V-positive cells without 
inducing necrotic LDH release in CRC cells. In the in vivo 
experiments, the number of cleaved caspase-3-positive cells 
increased significantly in the TP4O group compared with 
that in the control group. These results indicated that TP4O 
induced cell death in human CRC cell lines by apoptosis 
in vitro and in vivo.
In addition, the data from the present study revealed the 
source of ROS generation in the in vitro and in vivo TP4O 
treatments. Previous studies have demonstrated the anti-
oxidant activity of essential oils [reviewed in (7)], including 
TTO, which contains TP4O (27). Kim et al (28) investigated 
the antioxidant activity of TTO, and determined that three 
compounds of TTO serve important roles in the antioxidant 
mechanism, whereas TP4O did not possess antioxidant 
activity. In the current study, the hydroxyl radical was directly 
detected by ESR. Moreover, the protein levels of the major 
ROS scavengers and GPX1 were not decreased, which indi-
cates that the increase in ROS following TP4O treatment is 
not due to inhibition of the redox system but is the result of 
an increase in ROS production. The addition of antioxidant 
reagents inhibited TP4O-induced cell death. Taken together, 
these results suggested that the ROS induced following TP4O 
exposure serve a role in the anticancer effect of TP4O.
To maintain active proliferation, cancer cells produce 
more oxidative metabolites than normal cells (29). The redox 
system is activated in cancer, but cancer cells are not able to 
adapt to excess oxidative stress due to a decreased capacity 
for ROS metabolism compared with that of normal cells (29). 
However, normal cells produce lower levels of ROS than 
cancer cells; thus, they can adapt to increases in ROS (30,31). 
Previous reports have demonstrated that the differences 
in cellular metabolism of ROS could be a target for cancer 
treatment (31-37). There are three strategies to amplify 
intracellular oxidative stress. The first one is the inhibition of 
redox enzymes, i.e., GPX (35) or SOD (31). The second one is 
facilitating ROS production (36); the use of TP4O is included 
in this category. The third strategy is a combination of the two 
strategies mentioned above (37). These previous studies have 
revealed IC50 discrepancies between cancer cells and normal 
cells. The results of the present study support those from 
previous reports suggesting that ROS-mediated compounds 
have therapeutic potential against malignant neoplasms.
A number of limitations of the present study should be 
acknowledged. First, the underlying molecular mechanisms of 
ROS production by TP4O or the apoptotic pathway involved 
have not been detailed. As indicated by previous reports, 
excessive production and accumulation of ROS affects several 
mitogen-activated protein kinase signalling pathways, e.g., p38 
mitogen-activated protein kinase, extracellular signal-regulated 
Figure 4. Localization of ROS using MitoSOX Red™ Mitochondrial 
Superoxide Indicator fluorescence in HCT116 and RKO cells. HCT116 and 
RKO cells were treated with the indicated concentration of TP4O for 24 h. To 
locate the mitochondria generating ROS, the same cells were incubated with 
MitoTracker Green FM™ and MitoSOX Red™ Mitochondrial Superoxide 
Indicator. Images of merged MitoTracker Green FM™ and MitoSOX Red™ 
Mitochondrial Superoxide Indicator fluorescence were constructed to 
identify ROS generated by mitochondria. Scale bars represent 10 µm. ROS, 
reactive oxygen species; TP4O, terpinen-4-ol.
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kinase and c-Jun N-terminal kinase signalling pathways, which 
may be associated with ROS production (31,34,38,39). Thus, 
further studies are required to elucidate the association between 
TP4O and ROS generation or signalling pathways. Second, the 
activities of ROS scavengers were estimated using western blot 
analysis of SOD2 and GPX1; however, the actual activities of 
these enzymes or other redox systems have not been measured. 
The possibility that TP4O suppresses other redox systems cannot 
be ruled out. Third, ROS cause DNA damage and can promote 
tumorigenic signalling pathways (40). ROS are also known to 
lead to Alzheimer's disease (41), ischaemic vascular disease (42), 
non-alcoholic steatohepatitis (43) and other diseases (44). 
Although the data from the current study demonstrated that 
TP4O inhibited CRC xenograft growth without marked liver 
Figure 5. TP4O induces the activation of antioxidants, and antioxidant reagents rescue TP4O cytotoxicity. (A) Western blot analysis of antioxidant proteins. 
Lysates of HCT116 and RKO cells were examined following treatment with the indicated concentrations of TP4O for 24 h. GAPDH was used as a loading 
control. (B) HCT116 and RKO cells were treated with 0 or 1,000 µM TP4O in the presence of vehicle, 20 mM NAC, 20 µM EB or 100 µM MnTBAP for 24 h, 
and cell viability was measured by WST-8 assay. The values for each group were compared with those obtained with 0 µM TP4O. The data are represented 
as the mean ± standard deviation. **P<0.01. The results were obtained from three independent experiments. TP4O, terpinen-4-ol; MnTBAP, manganese (III) 
tetrakis (4-benzoic acid) porphyrin chloride; SOD2, superoxide dismutase 2; GPX1, glutathione peroxidase 1; NAC, N-acetyl-L-cysteine; EB, ebselen; ns, not 
significant. 
Figure 6. In vivo antitumor activity of TP4O in a xenograft model. (A) Schematic experimental design. A total of 2x106 HCT116 cells were subcutaneously 
injected into the right flank of ICR‑SCID mice receiving 250 µl of vehicle or TP4O (200 mg/kg) every 3 days by subcutaneous injection. Mice were sacrificed 
14 days after the first day of administration. (B) Tumor volume was measured over time. Increase in tumor volume was suppressed in the TP4O group. The data 
are presented as the mean ± standard deviation. **P<0.01. (C) Mice were sacrificed after 14 days, and body weight as well as serum levels of ALT and creatinine 
were measured. (D) Tumors were stained with antibodies against 8-OHdG and CC3. 8-OHdG- and CC3-stained positive areas were assessed by the ratio of 
the stained area to the entire tumor area in high‑magnification (x200) digital images in three randomly selected fields for each sample. Scale bars represent 
100 µm. TP4O, terpinen-4-ol; CC3, cleaved caspase-3; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; ALT, alanine aminotransferase.
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or renal injury in vivo, more precise assessment of the risk of 
the use of ROS for cancer therapy is required. The therapeutic 
concentration in the present study of TPO4 was similar to that of 
a previous report (17), which is considered high in clinical use. 
Therefore, consideration of a practical dose for future clinical 
use is crucial. As Shapira et al (17) reported, combination 
therapy may reduce the dose of TP4O and existing cancer drugs. 
Additionally, Berndtsson et al (45) reported the ROS accumula-
tion effect of oxaliplatin, which is typically used for the treatment 
of CRC (4). Thus, it is expected that combination therapy with 
TP4O and oxaliplatin would result in a synergistic effect. Upon 
sufficiently addressing the aforementioned issues, this new thera-
peutic strategy could be applicable in a clinical setting.
In conclusion, the results from the present study suggest 
that TP4O induces apoptosis in CRC cells through the genera-
tion of ROS in vitro and in vivo without damaging normal 
cells. Furthermore, TP4O is potentially useful for the future 
development of therapies against CRC.
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